• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Diabetes

Abbott partners with Berry Street to add nutrition coaching to Lingo

September 23, 2026 By Conor Hale

Abbott Lingo over-the-counter CGM next to packaging

Abbott (NYSE: ABT) is teaming up with Berry Street to offer dietitian support programs to Lingo users. Wearers of the over-the-counter continuous glucose monitor can now sign up for personalized nutrition coaching linked to their data trends, and schedule virtual one-on-one appointments with registered and insurance-covered dietitians. At the same time, Berry Street users will […]

Filed Under: Business/Financial News, Diabetes, Featured Tagged With: Abbott Laboratories, Berry Street, CGM, CGMs, continuous glucose monitor, digital health

Dexcom CFO to expand into COO role

September 15, 2026 By Conor Hale

This is a LinkedIn portrait photo of Dexcom CFO and COO Jereme Sylvain.

Dexcom‘s (Nasdaq:DXCM) C-suite is seeing another of its members take on multiple roles. Its chief financial officer will now also serve as chief operating officer. Jereme Sylvain joined the diabetes tech company in 2018, and has been its CFO and executive VP since 2021. His new COO hat will add oversight of Dexcom’s global operations […]

Filed Under: Business/Financial News, Diabetes, Featured Tagged With: Dexcom, Personnel Moves

Beta Bionics insulin patch pump scores FDA clearance

September 15, 2026 By Conor Hale

Beta Bionics Mint automated insulin delivery Patch Pump product image

Beta Bionics (NASDAQ: BBNX) has claimed an FDA clearance for its first patch pump insulin delivery system, amid plans to roll out an updated diabetes dosing algorithm and the launch of a new CGM partnership with Senseonics. The three-day, wearable Mint carries a 200-unit insulin reservoir as well as a combination of reusable and disposable […]

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA) Tagged With: Beta Bionics, Diabetes, FDA, Senseonics

Medtronic moves to divest final stake in MiniMed

September 14, 2026 By Conor Hale

This is a marketing image of the MiniMed Flex system and smartphone app, with Instinct sensor made by Abbott.

Medtronic (NYSE: MDT) is entering the final stretch of its long-running plan to split from its diabetes technology business, with the launch of an exchange offer that will allow stockholders to swap their company shares for those of the independent MiniMed (Nasdaq: MMED). With its catalog of insulin pumps, continuous glucose monitors and other diabetes […]

Filed Under: Business/Financial News, Diabetes, Featured, Uncategorized Tagged With: Medtronic, minimed

Dexcom adds former Stryker CFO to board

September 11, 2026 By Chris Newmarker

This is a LinkedIn profile picture of retired Stryker CFO Glenn Boehnlein who has joined Dexcom's board.

CGM maker Dexcom (Nasdaq: DXCM) is adding the former CFO of orthopedic and surgical device giant Stryker to its board of directors. Glenn Boehnlein’s appointment was in effect yesterday — the day of the announcement. Boehnlein’s addition expands the size of Dexcom’s board to 13. Boehnlein retired from Stryker last year after 22 years with […]

Filed Under: Business/Financial News, Diabetes, Featured Tagged With: Dexcom, Personnel Moves, stryker

MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance

September 1, 2026 By Chris Newmarker

MiniMed Flex insulin pump system product image

MiniMed (Nasdaq: MMED) today reported Street-beating first-quarter revenue, upping its full-year sales guidance as it notched an early European regulatory win. The Northridge, California–based diabetes tech company, spun out of Medtronic earlier this year, announced a CE mark for its next-gen, app-controlled MiniMed Flex insulin pump — well ahead of the company’s calendar 2026 year-end target. […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Regulatory/Compliance, Wall Street Beat Tagged With: automated insulin delivery system, CE mark, minimed

Abbott wins FDA authorization for dual glucose-ketone sensor

August 26, 2026 By Chris Newmarker

This is an Abbott marketing image of the Libre Duo 10 Day system.

Abbott (NYSE:ABT) announced today that the FDA has authorized its dual glucose-ketone sensing technology for people with diabetes. The authorization of the Libre Duo 10 Day system — which provides 10 days of wear time — comes three months after the company reported a CE mark in the EU for the Libre Duo and Libre […]

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA) Tagged With: abbott, CGMs

MiniMed Flex now integrated with Abbot’s Instinct sensor 

August 21, 2026 By Julia Rock-Torcivia

This is a marketing image of the MiniMed Flex system and smartphone app, with Instinct sensor made by Abbott.

MiniMed (Nasdaq: MMED) announced that the MiniMed Flex system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott. The MiniMed Flex system is MiniMed’s smallest and only app-controlled insulin pump. According to the company, Instinct is the world’s smallest sensor and offers up to 15 days of wear. Powered by SmartGuard technology, MiniMed Flex automatically adjusts insulin delivery, and the Meal Detection technology can […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: abbott, minimed

Senseonics sees activist investor take a major stake

August 17, 2026 By Chris Newmarker

Senseonics logo

Activist investor Sessa Capital has taken a sizeable stake in long-term, implantable CGM company Senseonics (NYSE: SENS), according to an SEC Schedule 13G filed today. The SEC filing lists Sessa directly owning 4,437,532 shares of Senseonics common stock, with warrants to buy another 8,000,000 shares of stock subject to a 9.9% blocker provision that prevents investors from […]

Filed Under: Business/Financial News, Diabetes, Featured, Wall Street Beat Tagged With: Senseonics, Sessa Capital

Abbott, Google to deliver glucose insights through artificial intelligence

August 11, 2026 By Chris Newmarker

Abbott (NYSE: ABT) is turning to Google’s artificial intelligence expertise to leverage more glucose insights for users of the Abbott Park, Illinois–based life science giant’s Lingo biowearable. Under a multiyear agreement announced today, ongoing glucose insights from Abbott’s Lingo biowearable will combine with Google Health’s technology to provide a more comprehensive view of people’s health. […]

Filed Under: Big Data, Business/Financial News, Diabetes, Featured, Technology Tagged With: abbott, Google

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 203
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS